STOCK TITAN

Enlivex raises about $500K in stock offering closing

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Enlivex Ltd. (ENLV) reported a registered direct offering of 5,703,462 ordinary shares (or pre-funded warrants in lieu) and ordinary warrants to purchase up to 5,703,462 shares. At the November 17, 2026 initial closing, the company issued 380,232 ordinary shares and warrants to purchase up to 380,232 shares. Investors irrevocably committed, subject only to continued listing on Nasdaq or another U.S. national securities exchange, to buy an additional $7.0 million of shares or pre-funded warrants, each with ordinary warrants, in 10 monthly $0.7 million closings from December 1, 2026 through September 1, 2027. The combined price is $1.315 per ordinary share or $1.314 per pre-funded warrant, each with an accompanying ordinary warrant.

Initial gross proceeds were approximately $0.5 million; aggregate gross proceeds would be approximately $7.5 million if all later closings occur, before estimated offering expenses and excluding ordinary warrant exercise proceeds. Some later closings may be postponed pending shareholder approval to increase authorized share capital, and any may be postponed if the registration statement is unavailable. Ordinary warrants are immediately exercisable at $1.578 per share and expire three years after the initial closing; pre-funded warrants are immediately exercisable at $0.001 per share with no expiration. Exercise is barred if a holder and its affiliates or group would beneficially own more than 19.99% immediately after exercise.

Filing Explained

The financing carries no placement-agent fee, and its warrants exclude ratchet or other financial anti-dilution provisions.

Enlivex reports that it used no placement agent and owes no placement-agent fees. Both warrant types have customary adjustments, but neither includes a ratchet or other financial anti-dilution provisions.

Net proceeds are intended for clinical, regulatory, manufacturing, research and development activities; potential acquisitions and in-licensing; and other general corporate purposes.

Offering securities 5,703,462 ordinary shares or pre-funded warrants in lieu, and ordinary warrants to purchase up to 5,703,462 ordinary shares Registered direct offering
Ordinary shares issued at initial closing 380,232 shares November 17, 2026
Ordinary warrants issued at initial closing 380,232 warrants Each warrant covers one ordinary share
Additional investor commitment $7.0 million Subject to continued listing; scheduled in 10 monthly closings
Aggregate gross proceeds Approximately $7.5 million Assuming all subsequent closings are completed; before estimated expenses and excluding ordinary warrant exercise proceeds
Combined purchase price $1.315 per ordinary share or $1.314 per pre-funded warrant Each paired with an ordinary warrant
Ordinary warrant exercise price $1.578 per ordinary share Ordinary warrants are immediately exercisable
Pre-funded warrant exercise price $0.001 per ordinary share Pre-funded warrants are immediately exercisable and have no expiration date
registered direct offering financial
"in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Pre-Funded Warrants financial
"Pre-Funded Warrants in lieu thereof"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statement regulatory
"effective shelf registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
beneficially owned financial
"shares beneficially owned by the holder"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
ratchet financial
"no such warrants contain any “ratchet”"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Enlivex (ENLV) raise in the offering?

The initial closing generated approximately $0.5 million in gross proceeds. Aggregate gross proceeds would be approximately $7.5 million if all subsequent closings are completed, before estimated offering expenses and excluding proceeds from ordinary warrant exercises.

When are Enlivex's (ENLV) additional offering closings scheduled?

The additional $7.0 million is scheduled in 10 monthly closings of $0.7 million each from December 1, 2026 through September 1, 2027. The investors’ commitment is subject only to continued listing on Nasdaq or another U.S. national securities exchange. Some closings may be postponed pending shareholder approval to increase authorized share capital, and any may be postponed if the registration statement is unavailable.

What are the terms of Enlivex's (ENLV) offering warrants?

Ordinary warrants are immediately exercisable at $1.578 per share and expire three years after the initial closing. Pre-funded warrants are immediately exercisable at $0.001 per share and have no expiration date. Exercise is barred if the holder, its affiliates and any group members would beneficially own more than 19.99% immediately afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: November 2026

 

Commission file number: 001-36578

 

ENLIVEX LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

As previously reported, on November 14, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) in connection with the issuance and sale by the Company in a registered direct offering (the “Offering”) of (i) 5,703,462 of the Company’s ordinary shares, par value NIS 96.00 per share (the “Ordinary Shares”) (or pre-funded warrants to purchase Ordinary Shares in lieu thereof (“Pre-Funded Warrants”)) and (ii) warrants to purchase up to 5,703,462 Ordinary Shares (the “Ordinary Warrants”, and together with the Pre-Funded Warrants, the “Warrants”), at a combined purchase price of $1.315 per Ordinary Share (or $1.314 per Pre-Funded Warrant) and accompanying Ordinary Warrant, pursuant to the Company’s effective shelf registration statement on Form F-3 (File No. 333-286956) and a related base prospectus, together with the related prospectus supplement, dated as of November 14, 2026 (such registration statement, prospectus and prospectus supplement, collectively, the “Registration Statement”), filed with the Securities and Exchange Commission. At the initial closing, the Company issued an aggregate of 380,232 Ordinary Shares and Ordinary Warrants to purchase up to 380,232 Ordinary Shares. Pursuant to the Securities Purchase Agreement, the Investors have also irrevocably committed, subject only to the continued listing of the Ordinary Shares on Nasdaq or another U.S. national securities exchange, to purchase an additional $7.0 million of Ordinary Shares (or Pre-Funded Warrants in lieu thereof) and accompanying Ordinary Warrants at the same price in 10 monthly closings of $0.7 million each, scheduled to occur from December 1, 2026 through September 1, 2027. Certain of the subsequent closings may be postponed until the Company’s receipt of shareholder approval of an increase in its authorized share capital, and any subsequent closing may be postponed if the Registration Statement is not then available.

 

The Ordinary Warrants have an exercise price of $1.578 per Ordinary Share, are immediately exercisable and will expire three years following the initial closing date, including Ordinary Warrants issued at the subsequent closings. Each Pre-Funded Warrant has an exercise price of $0.001 per Ordinary Share, is immediately exercisable and may be exercised at any time and has no expiration date. The Ordinary Warrants and the Pre-Funded Warrants are subject to customary adjustments; however, no such warrants contain any “ratchet” or other financial antidilution provisions. None of the Warrants may be exercised if the aggregate number of Ordinary Shares beneficially owned by the holder thereof, together with its affiliates and any person acting as a group with the holder or its affiliates, would exceed 19.99% immediately after exercise thereof.

 

The Offering was made directly by the Company, without a placement agent, underwriter, broker or dealer, and no placement agent fees are payable. The initial closing of the Offering occurred on November 17, 2026.

 

The gross proceeds from the initial closing of the Offering were approximately $0.5 million, and the aggregate gross proceeds from the Offering, assuming all subsequent closings are completed, will be approximately $7.5 million, in each case before deducting estimated expenses relating to the Offering and excluding any proceeds from the exercise of the Ordinary Warrants. The Company intends to use the net proceeds from the Offering for clinical, regulatory, manufacturing, and research and development activities; potential acquisitions and in-licensing; and other general corporate purposes.

 

The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement.

 

The foregoing description of the Securities Purchase Agreement, the Ordinary Warrants and the Pre-Funded Warrants is only a summary and is qualified in its entirety by reference to the complete text of the form of Securities Purchase Agreement, the form of Ordinary Warrant and the form of Pre-Funded Warrant, copies of which are attached as Exhibit 10.1, Exhibit 4.1 and Exhibit 4.2, respectively, to this Report on Form 6-K and are incorporated by reference herein, and such description and exhibits are incorporated by reference into the Company’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926, File No. 333-286956, File No. 333-292417, File No. 333-294284, File No. 333-295215 and File No. 333-298071), filed with the Securities and Exchange Commission.

 

Copies of the opinion of FISCHER (FBC & Co) regarding the validity of the Ordinary Shares issued at the initial closing and the Ordinary Shares issuable upon exercise of the Ordinary Warrants issued at the initial closing, and the opinion of Greenberg Traurig, LLP regarding the validity of the Warrants are filed as Exhibit 5.1 and Exhibit 5.2, respectively, to this Report on Form 6-K and are incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-286956) filed with the Securities and Exchange Commission.

 

Neither this Report on Form 6-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy the securities described herein or therein.

 

Exhibit Number   Description
4.1   Form of Ordinary Warrant
4.2   Form of Pre-Funded Warrant
5.1   Opinion of FISCHER (FBC & Co)
5.2   Opinion of Greenberg Traurig, LLP
10.1   Form of Securities Purchase Agreement
23.1   Consent of FISCHER (FBC & Co) (set forth in Exhibit 5.1)
23.2   Consent of Greenberg Traurig, LLP (set forth in Exhibit 5.2)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Ltd.
  (Registrant)
   
  By: /s/ Oren Hershkovitz
  Name: Oren Hershkovitz
  Title: Chief Executive Officer

 

Date: November 17, 2026

 

2

 

Filing Exhibits & Attachments

5 documents

Keep reading